Autres avocats qui pourraient vous intéresser
Dr. Stefanie Greifeneder
Stefanie is an expert in all regulatory, commercial and contractual matters in the pharmaceutical, medical device and biotech sector as well as in compliance-relevant topics in this area. She advises on the drafting and negotiation of complex and cross-border licensing agreements (out-licensing and in-licensing), research and development collaborations, manufacturing and distribution agreements as well as clinical trial agreements and with CROs.
In M&A and private equity transactions in the life sciences sector, she advises on all regulatory and contractual issues.
Afficher le CV complet
Masquer le CV complet
Voir plus
Moins
Voir plus
Moins
Carrière
| Since 2023 | Partner, Taylor Wessing |
| 2013 - 2023 | Partner, Fieldfisher, Munich |
| 2012 - 2013 | Counsel, Salans LLP, Frankfurt am Main |
| 2010 - 2012 | Senior Associate, Raupach, Frankfurt am Main |
| 2004 - 2009 | Associate, Ashurst LLP, Munich |
Formation
| 2004 - 2008 | Doctoral degree, dissertation on „Health and Nutrition Claims on Foods“ |
| 2004 | Admission as a lawyer |
| 2004 | Second State Examination, Munich |
| 2002 | First State Examination, Munich |
| 1997 - 2002 | Legal Studies at Ludwig-Maximilians-University Munich |
Langues étrangères
| English |
Actualités et publications récentes
Sciences de la vie et Santé
Cliquer ici pour en savoir plus
R&D Collaborations | Coffee Break Life Sciences Start-ups #4
18 avril 2024
In-depth analysis
Brevets et innovation
Cliquer ici pour en savoir plus
Important for start-ups: Confidentiality Agreements and Material Transfer Agreements (MTAs)
27 mars 2024
Briefing
Fusions et acquisitions d’entreprises et marchés financiers internationaux
Cliquer ici pour en savoir plus
Bertelsmann Investments acquires pharma tech company EXTEDO with Taylor Wessing
27 février 2024
par plusieurs auteurs
Sciences de la vie et Santé
Cliquer ici pour en savoir plus
Your safe path through the contract jungle: CDAs, MTAs & Co. | Coffee Break Life Sciences Start-ups #1
30 janvier 2024
In-depth analysis